Thiel E, Schwartz S
Medizinische Klinik III, Hämatologie, Onkologie und Transfusionsmedizin, Charité, Universitätsmedizin Berlin, Campus Benjamin Franklin, Freie Universität, Hindenburgdamm 30, D-12200 Berlin, Germany.
Mycoses. 2003;46 Suppl 2:3-7.
Invasive aspergillosis causes a markable part of infection-associated morbidity and mortality in immunocompromised patients. For none of hitherto available antimycotic agents a significant superiority could be demonstrated which all are characterised by unsatisfactory response rates. The newly developed and approved voriconazole is characterized by broad antifungal activity against numerous yeasts and filamentous fungi, including Aspergillus species. Voriconazole is available for intravenous administration and shows excellent bioavailability with oral application. The profile of toxicity is typical for azoles with the particularity of causing obviously substance-specific transient, benign visual disturbances. In clinical studies could be shown that voriconazole is significantly superior to the previous antimycotic standard, amphotericin B, with regard to therapy response and survival. In patients with invasive aspergillosis the therapy response with voriconazole is about 45% even in otherwise therapy-resistant cases.
侵袭性曲霉病在免疫功能低下患者的感染相关发病率和死亡率中占相当大的比例。迄今为止，尚无一种抗真菌药物能显示出显著优势，所有现有药物的特点都是有效率不尽人意。新开发并获批的伏立康唑具有广泛的抗真菌活性，可对抗多种酵母菌和丝状真菌，包括曲霉菌种。伏立康唑有静脉注射剂型，口服时生物利用度极佳。其毒性特征与唑类药物典型特征相符，特殊之处在于会引起明显的、特定药物所致的短暂良性视觉障碍。临床研究表明，在治疗反应和生存率方面，伏立康唑显著优于先前的抗真菌标准药物两性霉素B。在侵袭性曲霉病患者中，即使是在其他治疗耐药的病例中，伏立康唑的治疗有效率约为45%。
